ConductScience.org, home

Comparison · NCT00234065-c27a19d9

Cilostazol vs Aspirin: Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Cilostazol vs Aspirin: Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease. Trial comparisons, record NCT00234065-c27a19d9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00234065-c27a19d9

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.06430.05240.0788wilson
Risk in group 20.07720.0640.0927wilson
Risk difference, group 1 minus group 2-0.0128-0.03240.00669newcombe hybrid score
Risk ratio, group 1 over group 20.8340.6331.1log
Odds ratio, group 1 over group 20.8220.6111.11log
Number needed to treat, for one fewer participant with the outcome on Cilostazol than on Aspirin77.9from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Cilostazolcilostazol, oral tablet, 100 mg cilostazol861,337OG000
Group 2AspirinAspirin, oral tablet, 81 mg aspirin1031,335OG001

Outcome

Type
SECONDARY
Title
Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease
Description
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction or the first occurrence of transient ischaemic attack. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.
Time frame
From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
Population
Analyses were done using the full analysis set (FAS) of patients, as predetermined in the protocol. The full analysis set excluded patients who failed to satisfy inclusion criteria and those who violated exclusion criteria.

Source ClinicalTrials.gov

Trial

Title
Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
NCT number
NCT00234065
Phases
PHASE4
Conditions
Cerebral Infarction
Interventions
Cilostazol, Aspirin
Lead sponsor
Otsuka Pharmaceutical Co., Ltd.
Results first posted
2011-05-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00234065-c27a19d9